Advertisement
BCTX vs CANF
Which Stock Would AI Choose? BriaCell Therapeutics (BCTX) vs. Can-Fite BioPharma (CANF) Stock Comparison
Key Takeaways
- Both BCTX and CANF are clinical-stage biotechnology companies with pre-revenue business models, making their valuations heavily dependent on clinical trial milestones and financing events.
- BCTX has shown comparatively firmer relative momentum in recent weeks, while CANF has experienced steeper declines and more pronounced financing-driven dilution pressure.
- Tickeron AI Verdict: Based on trend consistency, stability, and catalyst quality, the AI currently favors BCTX over CANF.
- Risk profiles diverge on pipeline breadth and regulatory status: BCTX is anchored by a pivotal Phase 3 breast cancer program, while CANF spans multiple late-stage indications with earlier-stage readouts still pending.
- For more detail, explore the BCTX Major News and BCTX Today's Price Move pages, plus the CANF Major News and CANF Today's Price Move pages.
- To see which automated strategies are leading in the current environment, visit the curated Trending AI Robots page.
Introduction
This stock comparison examines two clinical-stage biotechnology names that frequently attract attention from speculative and event-driven traders: BriaCell Therapeutics and Can-Fite BioPharma. Although both operate in oncology and inflammatory disease drug development, they differ markedly in pipeline focus, market positioning, and recent price behavior. Investors weighing small-cap biotech opportunities — where a single clinical readout or financing event can move a stock by double digits — may find this relative performance analysis useful. By reviewing each company's business model, catalysts, and momentum, readers can better assess how BCTX and CANF compare on a risk-adjusted basis in the current market environment.
BCTX Overview and Recent Performance
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company headquartered in West Vancouver, Canada, developing targeted immunotherapies for cancer. Its lead candidate, Bria-IMT, is an off-the-shelf cell-based immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, often combined with an immune checkpoint inhibitor. The company is also advancing a personalized "off-the-shelf" platform known as Bria-OTS/OTS+ and a soluble CD80 protein program.
In recent weeks, BCTX has maintained a comparatively constructive tone. The company presented positive preclinical data across several posters at the SITC 2026 meeting, reported circulating immune biomarker findings at ESMO, and received an independent data safety monitoring board recommendation to continue its Phase 3 study — the seventh consecutive favorable safety review. These developments, alongside an "Immunotherapy Solution of the Year" industry award, have supported sentiment. The stock has traded in a modest single-digit-dollar range with elevated volatility, and its year-to-date return has been positive relative to its 52-week range, though it remains a pre-revenue company with ongoing losses and a reliance on external funding.
CANF Overview and Recent Performance
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petach-Tikva, Israel, developing orally administered small-molecule drugs. Its pipeline is anchored by two lead candidates: Piclidenoson, in a pivotal Phase 3 study for psoriasis, and Namodenoson, in Phase 3 for advanced liver cancer (hepatocellular carcinoma), with additional programs in pancreatic cancer, MASH (metabolic dysfunction-associated steatohepatitis), and obesity.
Recent market activity for CANF has been more challenging. The company presented final positive Phase 2a pancreatic cancer data for Namodenoson at ESMO 2026 and announced plans to pursue global licensing and partnerships at BIO-Europe 2026. However, these catalysts were offset by financing events, including a repriced warrant exercise that generated roughly $4 million in gross proceeds at a reduced exercise price — a move that introduced dilution and pressured the share price. The stock has declined substantially over the past year, with steep drawdowns across one-month, year-to-date, and twelve-month periods, reflecting ongoing losses, declining revenue, and investor caution around balance-sheet strength.
Trending AI Robots
Tickeron maintains a library of hundreds of AI trading bots that monitor and trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of covered symbols. Because market conditions change constantly, only a curated subset earns a place in the Trending AI Robots section — the bots currently judged best suited to today's market environment. These automated systems vary from short-term momentum strategies to longer-horizon trend followers, with differing win rates, trade frequencies, and risk profiles. Traders comparing names like BCTX and CANF may find value in observing how these algorithms evaluate volatility, catalyst timing, and trend strength across small-cap biotech. To review the currently featured strategies, visit the Trending AI Robots page.
Head-to-Head Comparison
The two companies diverge on several structural dimensions. BCTX is a cell-therapy platform play centered on a single lead indication (metastatic breast cancer), giving it a concentrated catalyst profile; success or failure of the Phase 3 program carries outsized influence. CANF, by contrast, operates a diversified oral small-molecule pipeline spanning psoriasis, liver cancer, pancreatic cancer, and metabolic disease, which spreads risk but also stretches limited resources across multiple trials.
On momentum, BCTX has held up better recently, benefiting from a stream of favorable safety and data disclosures. CANF's price action has been weighed down by dilution from warrant exercises and a longer downward trend, even as its clinical data has been broadly encouraging. Financing is a shared vulnerability for both pre-revenue companies, but the market has penalized CANF more sharply for its capital-raising approach. In terms of sector exposure, both sit within oncology-adjacent biotechnology, yet BCTX leans toward immunotherapy while CANF emphasizes small-molecule A3 adenosine receptor agonists — a mechanism with additional applications in inflammation and metabolism. Sentiment currently appears steadier around BCTX, whereas CANF faces the dual challenge of rebuilding investor confidence and funding its pipeline.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently favor BCTX over CANF. The assessment reflects BCTX's relatively more consistent recent trend, a steadier catalyst stream from its pivotal program, and less pronounced dilution-related pressure. CANF retains a broader clinical pipeline and meaningful long-term optionality, but its steeper price decline and financing-driven volatility make its near-term risk profile less favorable in an algorithmic framework. This is a probabilistic, relative positioning statement rather than a definitive prediction: small-cap biotech remains highly volatile, and either stock's trajectory could shift quickly with new clinical data or capital events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCTX is a Hold and CANF is a Hold.
BCTX's RSI Oscillator recovers from oversold territory
The RSI Oscillator for BCTX moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 39 of the 44 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BCTX as a result. In 81 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for BCTX just turned positive on November 06, 2026. Looking at past instances where BCTX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCTX advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
BCTX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCTX crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
BCTX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.428) is normal, around the industry mean (3.498). P/E Ratio (-4.702) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CANF's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CANF turned positive on November 02, 2026. Looking at past instances where CANF's MACD turned positive, the stock continued to rise in 31 of 39 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CANF's RSI Oscillator exited the oversold zone, 35 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 71 cases where CANF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on CANF as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANF advanced for three days, in 153 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CANF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CANF entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.715) is normal, around the industry mean (3.498). P/E Ratio (-0.349) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.621) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CANF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CANF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCTX | CANF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 86 | |
P/E GROWTH RATING 1..100 | 56 | 9 | |
SEASONALITY SCORE 1..100 | 18 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCTX's Valuation (23) in the null industry is in the same range as CANF (54) in the Biotechnology industry. This means that BCTX’s stock grew similarly to CANF’s over the last 12 months.
BCTX's Profit vs Risk Rating (100) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that BCTX’s stock grew similarly to CANF’s over the last 12 months.
BCTX's SMR Rating (99) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that BCTX’s stock grew similarly to CANF’s over the last 12 months.
BCTX's Price Growth Rating (62) in the null industry is in the same range as CANF (86) in the Biotechnology industry. This means that BCTX’s stock grew similarly to CANF’s over the last 12 months.
CANF's P/E Growth Rating (9) in the Biotechnology industry is somewhat better than the same rating for BCTX (56) in the null industry. This means that CANF’s stock grew somewhat faster than BCTX’s over the last 12 months.
| BCTX | CANF | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| Advances ODDS (%) | 6 days ago 79% | 3 days ago 77% |
| Declines ODDS (%) | 2 days ago 86% | 16 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCTX’s FA Score shows that 1 FA rating(s) are green while CANF’s FA Score has 1 green FA rating(s).
- BCTX’s FA Score: 1 green, 4 red.
- CANF’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCTX’s TA Score shows that 4 TA indicator(s) are bullish while CANF’s TA Score has 6 bullish TA indicator(s).
- BCTX’s TA Score: 4 bullish, 6 bearish.
- CANF’s TA Score: 6 bullish, 2 bearish.
Price Growth
BCTX (@Biotechnology) experienced а +22.59% price change this week, while CANF (@Biotechnology) price change was +2.47% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
BCTX is expected to report earnings on Dec 10, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCTX has been loosely correlated with CANF. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCTX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To BCTX | 1D Price Change % | ||
|---|---|---|---|---|
| BCTX | 100% | -1.07% | ||
| CANF - BCTX | 59% Loosely correlated | -1.19% | ||
| ENVB - BCTX | 50% Loosely correlated | +4.86% | ||
| TECX - BCTX | 47% Loosely correlated | +0.37% | ||
| ALLR - BCTX | 44% Loosely correlated | -3.49% | ||
| TAOX - BCTX | 35% Loosely correlated | -5.15% | ||
More | ||||
CANF and
Correlation & Price change
A.I.dvisor indicates that over the last year, CANF has been closely correlated with GNPX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To CANF | 1D Price Change % | ||
|---|---|---|---|---|
| CANF | 100% | -1.19% | ||
| GNPX - CANF | 93% Closely correlated | +1.46% | ||
| ICU - CANF | 91% Closely correlated | -3.06% | ||
| MLEC - CANF | 89% Closely correlated | N/A | ||
| LONA - CANF | 78% Closely correlated | -10.07% | ||
| NCEL - CANF | 62% Loosely correlated | +4.00% | ||
More | ||||